Literature DB >> 30517762

Histopathological and Molecular Signatures of a Mouse Model of Acute-on-Chronic Alcoholic Liver Injury Demonstrate Concordance With Human Alcoholic Hepatitis.

Shinji Furuya1, Joseph A Cichocki1, Kranti Konganti2, Kostiantyn Dreval3, Takeki Uehara4, Yuuki Katou4, Hisataka Fukushima1, Hiroshi Kono5, Igor P Pogribny6, Josepmaria Argemi7, Ramon Bataller7, Ivan Rusyn1.   

Abstract

Human alcoholic hepatitis (AH) carries a high mortality rate. AH is an acute-on-chronic form of liver injury characterized by hepatic steatosis, ballooned hepatocytes, neutrophil infiltration, and pericellular fibrosis. We aimed to study the pathogenesis of AH in an animal model which combines chronic hepatic fibrosis with intragastric alcohol administration. Adult male C57BL6/J mice were treated with CCl4 (0.2 ml/kg, 2×weekly by intraperitoneal injections for 6 weeks) to induce chronic liver fibrosis. Then, ethyl alcohol (up to 25 g/kg/day for 3 weeks) was administered continuously to mice via a gastric feeding tube, with or without one-half dose of CCl4. Liver and serum markers and liver transcriptome were evaluated to characterize acute-on-chronic-alcoholic liver disease in our model. CCl4 or alcohol treatment alone induced liver fibrosis or steatohepatitis, respectively, findings that were consistent with expected pathology. Combined treatment resulted in a marked exacerbation of liver injury, as evident by the development of inflammation, steatosis, and pericellular fibrosis, pathological features of human AH. E. coli and Candida were also detected in livers of mice cotreated with CCl4 and alcohol, indicating pathogen translocation from gut to liver, similar to human AH. Importantly, liver transcriptomic changes specific to combined treatment group demonstrated close concordance with pathways perturbed in patients with severe AH. Overall, mice treated with CCl4 and alcohol displayed key molecular and pathological characteristics of human AH-pericellular fibrosis, increased hepatic bacterial load, and dysregulation of the same molecular pathways. This model may be useful for developing therapeutics for AH.
© The Author(s) 2018. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  ethanol; fibrosis; liver; systems toxicology; transnational

Mesh:

Substances:

Year:  2019        PMID: 30517762      PMCID: PMC6657579          DOI: 10.1093/toxsci/kfy292

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  55 in total

Review 1.  Liver fibrosis in alcoholic liver disease.

Authors:  Ramon Bataller; Bin Gao
Journal:  Semin Liver Dis       Date:  2015-05-14       Impact factor: 6.115

2.  The DEN and CCl4 -Induced Mouse Model of Fibrosis and Inflammation-Associated Hepatocellular Carcinoma.

Authors:  Takeki Uehara; Igor P Pogribny; Ivan Rusyn
Journal:  Curr Protoc Pharmacol       Date:  2014-09-02

3.  Evaluation of fluorescence in situ hybridization for the detection of bacteria in feline inflammatory liver disease.

Authors:  David C Twedt; John Cullen; Kelly McCord; Stephanie Janeczko; Julie Dudak; Kenny Simpson
Journal:  J Feline Med Surg       Date:  2013-07-24       Impact factor: 2.015

4.  Blood culture-positive infections in patients with alcoholic hepatitis.

Authors:  Pernille Glahn Wernlund; Sidsel Støy; Lars Lemming; Hendrik Vilstrup; Thomas Damgaard Sandahl
Journal:  Scand J Infect Dis       Date:  2014-10-07

5.  Mouse model of chronic and binge ethanol feeding (the NIAAA model).

Authors:  Adeline Bertola; Stephanie Mathews; Sung Hwan Ki; Hua Wang; Bin Gao
Journal:  Nat Protoc       Date:  2013-02-28       Impact factor: 13.491

Review 6.  Alcoholic hepatitis: Translational approaches to develop targeted therapies.

Authors:  Pranoti Mandrekar; Ramon Bataller; Hidekazu Tsukamoto; Bin Gao
Journal:  Hepatology       Date:  2016-04-15       Impact factor: 17.425

7.  Beef fat prevents alcoholic liver disease in the rat.

Authors:  A A Nanji; C L Mendenhall; S W French
Journal:  Alcohol Clin Exp Res       Date:  1989-02       Impact factor: 3.455

8.  Enriching the gene set analysis of genome-wide data by incorporating directionality of gene expression and combining statistical hypotheses and methods.

Authors:  Leif Väremo; Jens Nielsen; Intawat Nookaew
Journal:  Nucleic Acids Res       Date:  2013-02-26       Impact factor: 16.971

9.  Adenosine 2A receptor antagonist prevented and reversed liver fibrosis in a mouse model of ethanol-exacerbated liver fibrosis.

Authors:  Dian J Chiang; Sanjoy Roychowdhury; Katelyn Bush; Megan R McMullen; Sorana Pisano; Kathryn Niese; Mitchell A Olman; Michele T Pritchard; Laura E Nagy
Journal:  PLoS One       Date:  2013-07-18       Impact factor: 3.240

10.  Alterations of the Ileal and Colonic Mucosal Microbiota in Canine Chronic Enteropathies.

Authors:  Eric Cassmann; Robin White; Todd Atherly; Chong Wang; Yaxuan Sun; Samir Khoda; Curtis Mosher; Mark Ackermann; Albert Jergens
Journal:  PLoS One       Date:  2016-02-03       Impact factor: 3.240

View more
  5 in total

1.  Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis.

Authors:  Josepmaria Argemi; Maria U Latasa; Stephen R Atkinson; Ilya O Blokhin; Veronica Massey; Joel P Gue; Joaquin Cabezas; Juan J Lozano; Derek Van Booven; Aaron Bell; Sheng Cao; Lawrence A Vernetti; Juan P Arab; Meritxell Ventura-Cots; Lia R Edmunds; Constantino Fondevilla; Peter Stärkel; Laurent Dubuquoy; Alexandre Louvet; Gemma Odena; Juan L Gomez; Tomas Aragon; Jose Altamirano; Juan Caballeria; Michael J Jurczak; D Lansing Taylor; Carmen Berasain; Claes Wahlestedt; Satdarshan P Monga; Marsha Y Morgan; Pau Sancho-Bru; Philippe Mathurin; Shinji Furuya; Carolin Lackner; Ivan Rusyn; Vijay H Shah; Mark R Thursz; Jelena Mann; Matias A Avila; Ramon Bataller
Journal:  Nat Commun       Date:  2019-07-16       Impact factor: 14.919

2.  Transcriptomic Cross-Species Analysis of Chronic Liver Disease Reveals Consistent Regulation Between Humans and Mice.

Authors:  Christian H Holland; Ricardo O Ramirez Flores; Maiju Myllys; Reham Hassan; Karolina Edlund; Ute Hofmann; Rosemarie Marchan; Cristina Cadenas; Jörg Reinders; Stefan Hoehme; Abdel-Latif Seddek; Steven Dooley; Verena Keitel; Patricio Godoy; Brigitte Begher-Tibbe; Christian Trautwein; Christian Rupp; Sebastian Mueller; Thomas Longerich; Jan G Hengstler; Julio Saez-Rodriguez; Ahmed Ghallab
Journal:  Hepatol Commun       Date:  2021-08-28

Review 3.  Animal models applied to acute-on-chronic liver failure: Are new models required to understand the human condition?

Authors:  Jaciara Fernanda Gomes Gama; Liana Monteiro da Fonseca Cardoso; Jussara Machado Lagrota-Candido; Luiz Anastacio Alves
Journal:  World J Clin Cases       Date:  2022-03-26       Impact factor: 1.337

4.  A Novel Mouse Model of Acute-on-Chronic Cholestatic Alcoholic Liver Disease: A Systems Biology Comparison With Human Alcoholic Hepatitis.

Authors:  Shinji Furuya; Josepmaria Argemi; Takeki Uehara; Yuuki Katou; Derrick E Fouts; Bernd Schnabl; Laurent Dubuquoy; Abha Belorkar; Rajanikanth Vadigepalli; Hiroshi Kono; Ramon Bataller; Ivan Rusyn
Journal:  Alcohol Clin Exp Res       Date:  2019-11-28       Impact factor: 3.928

5.  Dual therapy with zinc acetate and rifaximin prevents from ethanol-induced liver fibrosis by maintaining intestinal barrier integrity.

Authors:  Yuki Fujimoto; Kosuke Kaji; Norihisa Nishimura; Masahide Enomoto; Koji Murata; Soichi Takeda; Hiroaki Takaya; Hideto Kawaratani; Kei Moriya; Tadashi Namisaki; Takemi Akahane; Hitoshi Yoshiji
Journal:  World J Gastroenterol       Date:  2021-12-28       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.